Related Experiment Video
Updated: Jan 30, 2026

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
Newest evidence for tetrahydrocannabinol:cannabidiol oromucosal spray from randomized clinical trials
1Neurology Department, Charles University, 3rd Faculty of Medicine and Thomayer Hospital, Czechia.
Abstract:
Subsequent to EMA approval of tetrahydrocannabinol (THC): cannabidiol (CBD) oromucosal spray based on results of various studies, including an enriched-design clinical trial, two newer postapproval randomized trials have confirmed its efficacy and safety for treating resistant multiple sclerosis spasticity, while simultaneously addressing specific authorities' concerns. A double-blind, placebo-controlled, Phase IV trial, conducted as part of the EMA's risk management plan, found no effect of THC:CBD spray on cognition and mood after 50 weeks of treatment. In the Sativex® as add-on therapy versus further optimized first-line ANTispastics (SAVANT) study, add-on THC:CBD spray was significantly more effective than readjusting standard antispasticity therapy and provided new evidence of efficacy as requested by German authorities. SAVANT results support practical recommendations for treating resistant multiple sclerosis spasticity in daily practice.
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
The Evidence for Evolution
Statistical Software for Data Analysis and Clinical Trials
Trial and Error and Algorithm
Random Error

